Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 101

Next Previous
X
Search
Drug Profile

MT 101

Alternative Names: ATAK CAR monocytes therapy - Myeloid Therapeutics; MT-101

Latest Information Update: 29 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myeloid Therapeutics
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral T-cell lymphoma

Most Recent Events

  • 13 Nov 2023 Myeloid Therapeutics temporarily suspends the phase I/II IMAGINE trial in Peripheral T-cell lymphoma (Second-line therapy or greater, Inoperable/Unresectable) in USA (IV, Infusion) (NCT05138458)
  • 17 Apr 2023 Efficacy and adverse events data from a phase I/II trial in Peripheral T cell lymphoma released by Myeloid Therapeutics
  • 31 Oct 2022 MT 101 receives Fast Track designation for Peripheral T-cell lymphoma [IV,Infusion] (Inoperable/Unresectable, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top